Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Freeport-McMoRan

JPMorgan Chase & Co

Procter & Gamble

UnitedHealth Group

We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.

5 Stocks to Watch on Solid Revenues in Last Reported Quarter

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S. One-year outcomes from the EXPAND G4 study, simultaneously published in JACC: Cardiovascular Interventions , reinforce durable safety and effectiveness of MitraClip™ with significant mitral regurgitation reduction ABBOTT PARK, Ill., Oct. 24, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease.

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Abbott Laboratories' business has underwhelmed investors in 2023, as testing numbers are down big. Growth in its medical devices was the only bright spot in the company's recent earnings report.

Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.

Baxter

Intuitive Surgical

Johnson & Johnson

Medtronic

Stryker

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.

The Value Deepens for Medtech Stocks: Reversal Imminent

Wegovy/Ozempic/Mounjaro seem to be driving adoption for ABT's glucose monitoring equipment, Libre, with 5M of global users by October 2023 (+11.1% YoY) and nearly 2M in the US. Its financial performance over the past few quarters in the Diabetes Medical Devices and Nutrition segments has also concurred with the CEO's promising commentary. ABT's other segments have similarly suggested a profitable growth trend, demonstrating why the stock deserves its premium valuation compared to the sector median.

Abbott Labs: Wegovy Is No Threat For Now

Abbott Laboratories reported solid growth across all segments in its third-quarter results, excluding its COVID diagnostics portfolio. The company's medical devices business, which includes its Diabetes Care portfolio, grew almost 29% in Q3 despite fears of competition from GLP-1 drugs.

Abbott Labs: Fear Is In The Air - That's Why I'm Bullish

U.S. medical device makers do not see a big impact of new weight-loss treatments on the sales of equipment used in procedures such as bariatric surgery due to the prohibitive costs of the drugs as well as reimbursement hurdles.

Medical device makers see limited hit from weight-loss drugs

Abbott is a well-diversified healthcare company with strong underlying revenue growth and a robust product pipeline.

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Anheuser-Busch InBev

Disney

Estee Lauder

NIKE

Nintendo

QUALCOMM

While there are many ways to position yourself in the market during this ambiguous juncture, one of the most straightforward approaches involves targeting blue-chip stocks to buy on the dip. By definition, blue chips represent industry stalwarts with strong financial backbones.

7 Blue-Chip Stocks to Buy on the Dip

CEO Robert Ford said more users of its glucose monitoring system were using the device while also taking new obesity drugs.

Abbott Earnings Show Obesity Drug Worries Are Overblown

Abbott Laboratories (NYSE:ABT ) Q3 2023 Earnings Call Transcript October 18, 2023 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Philip Boudreau - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Danielle Antalffy - UBS Joanne Wuensch - Citibank Vijay Kumar - Evercore ISI Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter 2023 Earnings Conference Call.

Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip

Abbott Laboratories (NYSE:ABT) shares rose after the healthcare technology company posted a third quarter earnings beat and provided strong full-year guidance. While revenue decreased 2.8% year-over-year to $10.1 billion due to the expected decline in COVID-19 testing-related sales, it topped Street expectations of $9.8 billion.

Abbott Laboratories 3Q earnings top estimates on strong medical devices sales growth

Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.15 per share a year ago.

Abbott (ABT) Beats Q3 Earnings and Revenue Estimates

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott (ABT) Reports Q3 Earnings: What Key Metrics Have to Say

Abbott Laboratories NYSE: ABT share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market to sell, but not now; the market is oversold and overextended with normalization at hand.

Oversold and Overextended, Abbott Laboratories is a Great Buy

Abbott stock rose moderately Wednesday after the company beat third-quarter expectations and raised the midpoint of its earnings view.

Abbott Raises Outlook, Boosted By 'Whopping' Growth Of Diabetes Device

Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year.

Abbott Stock Is Rising. Earnings Beat and Guidance Was Strong.

Abbott Laboratories shares ABT, -0.04% climbed 2.5% premarket on Wednesday after the healthcare products company posted a better-than-expected third-quarter profit and raised its earnings guidance for the full year. The company reported third quarter net income of $1.436 billion, or 82 cents per share, versus $1.435 billion, or 81 cents per share, in the year earlier period.

Abbott Labs shares rise as company beats earnings estimates, raises full-year guidance

Abbott Laboratories on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products.

Abbott beats profit estimates on strong sales of devices, diagnostics

Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 13.8 percent, reflects double-digit growth in each of the four major businesses ABBOTT PARK, Ill., Oct. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Abbott (ABT) Ahead of Earnings?

When volatility is high, it can be a good time to be an option seller rather than a buyer.

Earn Extra Cash On ABT Stock Earnings, But Careful With This Risk

Amgen

There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years.

Which Is A Better Pick – Abbott Stock Or Amgen?

Apple

AbbVie

Arbor Realty Trust

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Becton, Dickinson and Co.

Blackrock Inc

Bristol-Myers

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

CVS Health

Chevron

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.

News for Abbott Labs Stock (ABT)